Retatrutide and Cholesterol: A Post Hoc Look at 2 Trials
A post hoc paper in Diabetes, Obesity and Metabolism, dated 17 August 2026, revisited two phase 2 retatrutide trials with a narrower question in mind: what changed in lipoproteins, and what moved, if anything, in inflammatory markers. The lipid shifts, at least on paper, are large. Still, the setup matters, and the context should travel with the headline numbers.
Retatrutide is an investigational triple agonist at the GIP, GLP-1, and glucagon receptors. It has not been approved anywhere. Peptra Labs supplies retatrutide as reference material for laboratory research only, and nothing in this write-up should be read as advice for human use.
What the authors looked at
Two randomised, double-blind, placebo-controlled phase 2 trials formed the basis of the analysis.
Study 1 enrolled adults with obesity or overweight plus type 2 diabetes. Participants received once-weekly retatrutide, 0.5, 4, 8, or 12 mg, dulaglutide 1.5 mg, or placebo, over 36 weeks. Study 2 enrolled adults with clinical obesity without type 2 diabetes and assigned once-weekly retatrutide, 1, 4, 8, or 12 mg, or placebo, for 48 weeks.
Fasting blood was taken at baseline and during treatment. The analysis covered standard lipids, apolipoproteins, particle subclasses, and a set of inflammatory biomarkers. For statistics, the authors used mixed models for repeated measures and reported placebo-adjusted change from baseline. They set significance at a false discovery rate adjusted p value under 0.05.
Average BMI was 35.4 kg/m2 in Study 1 and 37.4 kg/m2 in Study 2. Trial registrations are NCT04881760 and NCT04867785.
The lipoprotein results
Across seven measures, the abstract reports significant reductions. It presents the results as paired values, first from Study 1 then from Study 2. One pair is described as “up to”, which reads as the largest placebo-adjusted reduction seen within the dose range rather than a single pooled effect across all arms.
| Measure | Study 1 | Study 2 |
|---|---|---|
| Non-HDL cholesterol | up to -21.0% | up to -26.9% |
| Apolipoprotein B | -21.4% | -24.2% |
| Total triglyceride-rich lipoprotein particles | -22.5% | -33.7% |
| Large triglyceride-rich lipoprotein particles | -84.4% | -76.6% |
| Triglyceride-rich lipoprotein cholesterol | -29.4% | -38.6% |
| Total LDL particles | -19.7% | -23.5% |
| Small LDL particles | -32.6% | -32.3% |
The large triglyceride-rich lipoprotein particle change is the eye-catcher, but it also needs the base rate alongside it. This subclass tends to sit at low concentrations, so an outsized percentage drop can still reflect a smaller absolute move. The abstract does not provide absolute values.
Two entries are worth treating as more than just another line in the table. Apolipoprotein B is a particle count marker, one molecule per atherogenic particle, and is often discussed as more direct than cholesterol concentration alone. Small LDL particles are the subclass most often discussed in relation to atherogenic risk. Both shifted downward in both trials.
Inflammation, where the trials part ways
This split is easy to miss and probably should not be.
In Study 2, the authors report significant drops in high-sensitivity C-reactive protein, -54.8%, and interleukin-6, -29.6%. In Study 1, they say comparable reductions did not meet statistical significance.
There are several differences between the studies that could plausibly play a role. Study 1 included people with type 2 diabetes and ran 36 weeks. Study 2 excluded diabetes, ran 48 weeks, and started with a higher mean BMI. The abstract does not try to pin down why the inflammation signals separated, and a summary should not pretend it can either.
What “post hoc” signals
The first line of the abstract labels this as post hoc, and that label changes how heavily the findings should be taken.
Post hoc means the analysis asks new questions of data collected for other primary aims. These trials were designed and powered for weight and glycaemic outcomes. Lipoproteins were measured, yes, but the studies were not built around them as primary hypotheses, and the comparisons in this analysis were laid out after the data were already in hand.
That is not the same as saying the numbers are wrong. The authors applied false discovery rate correction, which is a sensible check when many biomarkers are tested at once, and more restraint than some post hoc work shows. Still, the right framing is hypothesis-generating, not confirmatory.
A second limit is the nature of the endpoints. Lipoproteins and inflammatory biomarkers are associated with cardiovascular risk, they are not cardiovascular events. The authors’ own conclusion keeps that boundary: retatrutide was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk. Linked to risk is not the same as shown to reduce risk.
A similar distinction came up recently in a meta-analysis of blood pressure related adverse events for a different compound, where recorded events and measured physiology also needed separating.
Authorship and affiliation
Fourteen authors are listed. Twelve give Eli Lilly and Company, Indianapolis, as their affiliation, and two list the University of Glasgow and Monash University.
In other words, this is a post hoc look at sponsor-run trials, written mostly by sponsor scientists. That is normal and not automatically a flaw. It is background a reader should carry, just as they should carry the false discovery rate adjustment, and it is another reason to see the work as a careful readout of existing data rather than independent confirmation.
How it fits the broader retatrutide record
Phase 2 is still mid-story. A retatrutide trial in people with type 2 diabetes and inadequate glycaemic control appeared in The Lancet in June 2026. A body composition substudy from a phase 2 type 2 diabetes trial was published in The Lancet Diabetes and Endocrinology in 2025.
This lipoprotein analysis sits beside those papers as one more attempt to map what the triple agonist does beyond weight outcomes, which is where the wider class is being pushed. Our triple-agonist research peptide guide gathers mechanism and trial history in one place, and the documentation for our retatrutide reference material lays out the identity and purity fields that should anchor any laboratory work with the compound.
References
- Ruotolo G, Harris C, Lin Y, et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes, Obesity and Metabolism, 17 August 2026. doi 10.1111/dom.71200
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control. The Lancet, 13 June 2026
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group trial. The Lancet Diabetes and Endocrinology, August 2025
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
